Background: Hepatitis C virus (HCV) infection is a global health problem and a major cause of morbidity and mortality. The current study aimed to assess the correlation between the patients with the hepatitis C virus and their health-related quality of life. Descriptive design was used. Setting: Carried out at liver virology outpatient. Subject: A convenient sample of two hundred adult patients with HCV newly received Sofosbuvir and Daclatasvir. Tools: Interview questioner and medical data sheet and Short-Form health survey (SF-36) questionnaire. Results: An improvement in the total quality of life this appear through 51.0% of hepatitis patients were poor in quality of life before treatment with Sofosbuvir and Daclatasvir medication while (62.0%) of them become excellent in quality of life after 3 months from treatment with highly statistically significant differences. Also, there was a fair negative association between the duration of disease of the studied patients with their total quality of life measured by shortform of health before administration of treatment with Sofosbuvir and Daclatasvir. Conclusion: The study concluded that the administration of Sofosbuvir and Daclatasvir for patients had positive effect on their quality of life especially for newly diagnosed patients. Recommendation: The study recommended that early screening for hepatitis C to begin early suitable treatment.